Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Cboe UK CHF

Basilea Pharmaceutica AG (BSLNZ.XC)

Compare
42.62
-0.62
(-1.45%)
At close: April 3 at 4:19:45 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BSLNZ.XC

Recent News: BSLNZ.XC

View More
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
GlobeNewswire 20 days ago
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow

Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
GlobeNewswire last month
Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea

Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea
GlobeNewswire last month
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea

Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea
GlobeNewswire 2 months ago
Basilea provides portfolio update and outlook

Basilea provides portfolio update and outlook
GlobeNewswire 2 months ago
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
GlobeNewswire 3 months ago
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
GlobeNewswire 3 months ago
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
GlobeNewswire 6 months ago
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
GlobeNewswire 6 months ago
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
GlobeNewswire 6 months ago
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
GlobeNewswire 7 months ago
View More